Small Cap Biopharma Stocks: Momentum Looks Good for Gains
- Our bellwether ETFs for this group are: Ark Genomic Revolution (ARKG) up 3% 1m and 5% YTD; S&P SPDR Biotech( XBI) up 7.66% 1m and 3.79% YTD.
- Most of these picks have been screened for analyst ratings (buy or above) and adequate cash position
- Our strategy for trading after pre -screening is based on momentum.
- Our Small Cap Biotech Trading List as of 8/25 is based on a model we developed in 2024 and we are holding several stocks with good gains in our portfolio: ADPT, COGT, EYPT, GH, RYTM and SUPN. Many of our other picks were good trades or our currently near their 52 week highs BBIO, COGT, CYRX, CYTK, LGND,PTGX, RNA, ROIV, RZLT, TEM, VCYT.
The IBB looks like a favorable trend.
Three of our recent long trades are: Crescent Biopharma (CBIO) 13.69, Personalis (PSNL) 5.04, Xencor (XNCR) 8.37. All are in buying range now and have strong balance sheets,
Crescent Biopharma, Inc., (CBIO) an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.Market cap $190m.IND expected by Q4 2025. Pcash 1.29. Analyst rating 1.00.
Personalis, Inc. (PSNL) develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. Market cap $451M. Pcash 4.61, Analyst rating 1.21.
Xencor, Inc.,(XNCR) a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. Market cap 597M,Pcash 1.34,Analyst rating 1.50.